Stay updated with breaking news from I Mab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and...
/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...
Zurcher Kantonalbank Zurich Cantonalbank lowered its position in shares of I-Mab (NASDAQ:IMAB – Get Rating) by 13.5% in the first quarter, Holdings Channel reports. The institutional investor owned 9,171 shares of the company’s stock after selling 1,432 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in I-Mab were worth $149,000 as of its most […]
/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...
I-Mab (NASDAQ:IMAB – Get Rating) and Galera Therapeutics (NASDAQ:GRTX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership. Valuation and Earnings This table compares I-Mab and Galera Therapeutics’ […]